fat-2 Antibody

What is FAT2 and why is it significant in research contexts?

FAT2 (FAT atypical cadherin 2) is an atypical cadherin protein with a canonical human form comprising 4349 amino acid residues and a mass of 479.3 kDa. Its significance stems from its role in regulating cell migration, with subcellular localization primarily in the Golgi apparatus and cell membrane. FAT2 is notably expressed in the skin, oral mucosa, esophagus, cervix, and cerebellum. Recent research has established connections between FAT2 and the disease Spinocerebellar ataxia, making it an important target for neurological investigations . Understanding FAT2's function is fundamental to multiple research areas including developmental biology, cancer research, and neuroscience.

What are the common experimental applications for FAT2 antibodies?

FAT2 antibodies are employed across multiple experimental platforms including:

• Flow Cytometry: For quantification and sorting of cells expressing FAT2

• Immunocytochemistry (ICC): For subcellular localization studies in cultured cells

• Immunofluorescence (IF): For high-resolution visualization of FAT2 distribution

• Immunohistochemistry (IHC): For detection of FAT2 expression in tissue sections

The selection of the appropriate application depends on your research question, with IHC being particularly valuable for examining FAT2 distribution in native tissue architecture, while ICC/IF provides higher resolution for subcellular localization studies .

How can researchers differentiate between FAT2 and other FAT family members?

Distinguishing FAT2 from other FAT family proteins requires careful antibody selection and validation. When designing experiments, researchers should:

• Select antibodies raised against unique epitopes in FAT2 not conserved in other family members

• Validate antibody specificity using knockout/knockdown controls

• Perform parallel detection with multiple antibodies recognizing different epitopes

• Consider complementary RNA-level detection methods (RT-PCR, RNA-seq) to confirm target specificity

Cross-reactivity testing against recombinant FAT family proteins can provide additional validation of antibody specificity before proceeding with experimental applications.

What approaches are recommended for detecting FAT2 in tissues with low expression levels?

For tissues with low FAT2 expression, standard immunodetection may yield poor signal-to-noise ratios. Consider implementing:

• Signal amplification techniques such as tyramide signal amplification (TSA)

• Extended primary antibody incubation (overnight at 4°C) to increase binding efficiency

• Optimization of antigen retrieval methods (test both heat-mediated and enzymatic approaches)

• Use of highly sensitive detection systems (e.g., polymer-based detection with enhanced chromogens)

• Validation with in situ hybridization to confirm protein expression correlates with transcript levels

These approaches should be systematically optimized for each specific tissue type, as FAT2 expression patterns vary considerably between the skin, cervix, and cerebellum contexts .

How can researchers effectively visualize FAT2 localization at tricellular junctions?

Visualizing FAT2 at tricellular junctions requires specialized techniques. Based on studies using Fat2-GFP in Drosophila follicle cells, effective approaches include:

• Super-resolution microscopy techniques such as structured illumination microscopy (SIM) to resolve concentrated signals at junction points

• Co-labeling with established tricellular junction markers (e.g., tricellulin)

• Live-cell imaging with weakly expressed fluorescent fusion proteins to avoid overexpression artifacts

• Quantification of relative fluorescence intensity at tricellular junctions compared to bicellular contacts

• Time-lapse imaging to capture dynamic localization changes during development

Studies have demonstrated that Fat2-GFP accumulates at tricellular contacts in migrating follicle cells and shows significant enrichment at these junctions between developmental stages 5 and 9 .

What is the optimal fixation protocol for preserving FAT2 epitopes in tissue sections?

FAT2's large size and complex post-translational modifications necessitate careful fixation approach selection:

• Test multiple fixatives: 4% paraformaldehyde (PFA) is standard, but modified fixatives combining aldehydes and alcohols may better preserve epitopes

• Optimize fixation time: Excessive fixation can mask epitopes through cross-linking

• Consider dual fixation protocols: Brief fixation with glutaraldehyde (0.1-0.5%) followed by PFA may preserve membrane structures while maintaining antigenicity

• Cryopreservation vs. paraffin embedding: Compare both methods as glycosylated epitopes may be differently preserved

• Validate with positive control tissues known to express high FAT2 levels (e.g., cerebellum, skin)

The preservation of membrane-associated FAT2 is particularly challenging and may require specialized extraction buffers during sample preparation to reduce background while maintaining specific signal.

How can researchers investigate the interaction between FAT2 and the WAVE regulatory complex (WRC)?

Investigating FAT2-WRC interactions requires specialized biochemical and imaging approaches:

• Co-immunoprecipitation with antibodies against FAT2 and WRC components (e.g., Abi)

• Proximity ligation assay (PLA) to detect in situ protein-protein interactions

• FRET/BRET analysis with fluorescently tagged proteins to measure direct interactions

• Structured illumination microscopy to visualize co-localization at subcellular resolution

• Genetic manipulation of FAT2 WIRS motifs that mediate WRC binding

Research has demonstrated increasing overlap of Abi (a WRC component) and Fat2-GFP at tricellular contacts during Drosophila egg chamber development, with prominent overlap observable between stages 5 and 7 . In fat2 mutant cells, Abi localization is significantly reduced at the basal follicle side, indicating that Fat2 acts upstream to regulate WRC localization .

What approaches should be used to distinguish between post-translational modifications of FAT2?

FAT2 undergoes multiple post-translational modifications, particularly glycosylation. To investigate these modifications:

• Use specialized antibodies recognizing specific glycoforms

• Employ enzymatic deglycosylation (PNGase F, Endo H) prior to western blotting to assess contribution of N-linked glycans

• Implement lectin blotting to characterize glycan structures

• Apply mass spectrometry approaches for comprehensive PTM mapping

• Create site-directed mutants of predicted modification sites to assess functional impact

The large size of FAT2 (479.3 kDa) presents technical challenges for standard western blotting; gradient gels and specialized transfer conditions are recommended to accurately resolve and detect the fully modified protein .

How can researchers evaluate FAT2's role in collective cell migration?

To study FAT2's function in collective migration:

• Establish live-imaging systems with fluorescently labeled FAT2 in appropriate cell models

• Implement CRISPR/Cas9-mediated knockout or knockdown of FAT2

• Create domain-specific mutants to dissect functional regions

• Perform rescue experiments with wild-type vs. mutant constructs

• Quantify migration parameters (speed, directionality, coordination)

Studies in Drosophila have revealed that Fat2-GFP localizes at the tips of whip-like protrusions in migrating follicle cells, with striking overlap with junctional actin-rich protrusions. These observations suggest a role for FAT2 in organizing the actin cytoskeleton during collective migration .

How should researchers interpret FAT2 mutations in cancer genomic studies?

When analyzing FAT2 mutations in cancer contexts:

• Distinguish between passenger and driver mutations through functional validation

• Correlate mutation status with clinical outcomes across multiple datasets

• Perform multivariate analysis to assess independence from other prognostic factors

• Evaluate mutation frequency in the context of tumor mutation burden (TMB)

• Assess impact on immune cell infiltration and immunotherapy response

What methodological considerations are important when using FAT2 as a prognostic biomarker?

For FAT2 biomarker implementation:

• Standardize detection methods across laboratories (antibody clone, dilution, detection system)

• Establish clear scoring criteria for immunohistochemical evaluation

• Validate cutoff thresholds in independent patient cohorts

• Integrate FAT2 status with established clinicopathological parameters

• Develop combined biomarker panels rather than relying on FAT2 alone

Studies have demonstrated conflicting prognostic associations of FAT2 across different cancer types: better prognosis in UCEC , but worse outcomes in esophageal squamous cell carcinoma . These context-dependent effects necessitate careful validation in each specific cancer type.

What are the common pitfalls in FAT2 western blotting and how can they be addressed?

Western blotting for FAT2 presents several challenges:

• Size limitations: At 479.3 kDa, standard gel systems may not adequately resolve FAT2

  • Solution: Use low-percentage (3-5%) gels or gradient gels (3-8%)

  • Consider specialized high-molecular-weight transfer systems

• Degradation products: Large proteins are susceptible to proteolysis

  • Solution: Include multiple protease inhibitors during sample preparation

  • Compare fresh vs. frozen samples to assess degradation impact

• Extraction efficiency: Membrane proteins require specialized extraction

  • Solution: Test various detergent combinations (RIPA, NP-40, Triton X-100, SDS)

  • Consider sequential extraction protocols to maximize recovery

• Detection sensitivity: High-molecular-weight proteins transfer inefficiently

  • Solution: Extend transfer time or use semi-dry transfer systems

  • Implement enhanced chemiluminescence detection systems

Why might contradictory results emerge in FAT2 protein interaction studies?

Contradictory findings in protein interaction studies, as observed with FAT and its binding partners , may stem from:

• Expression system differences: Prokaryotic vs. eukaryotic expression affecting post-translational modifications

• Construct design: Incomplete protein domains or improper boundaries disrupting interaction surfaces

• Buffer conditions: Variations in salt concentration, pH, or detergents affecting weak interactions

• Methodological sensitivity: Different techniques (pull-down vs. ITC vs. NMR) have varying detection limits

• Cellular context: Additional cofactors or scaffolding proteins required in vivo but absent in vitro

As demonstrated in studies of the FAT domain interactions, biophysical binding assays often fail to reproduce interactions observed in cellular contexts, suggesting that post-translational modifications or additional cellular partners may be essential for these interactions .

How might single-cell approaches advance our understanding of FAT2 function?

Single-cell technologies offer promising avenues for FAT2 research:

• Single-cell RNA-seq to map FAT2 expression heterogeneity within tissues

• Single-cell proteomics to correlate FAT2 protein levels with transcriptional state

• Spatial transcriptomics to preserve tissue context while assessing expression patterns

• Live-cell imaging with endogenously tagged FAT2 to track dynamics in native contexts

• Clonal analysis to assess cell-autonomous vs. non-autonomous effects of FAT2 manipulation

These approaches could reveal previously unrecognized cell-type specific functions of FAT2 and help resolve conflicting findings across different experimental systems.

What are promising strategies for developing highly specific FAT2 antibodies?

Developing next-generation FAT2-specific antibodies could involve:

• Recombinant antibody technologies (phage display, yeast display) for higher specificity

• Selection of unique epitopes using bioinformatic approaches to minimize cross-reactivity

• Development of conformation-specific antibodies recognizing functional states

• Nanobody or single-domain antibody approaches for improved access to sterically hindered epitopes

• Rigorous validation across multiple species to ensure consistent cross-reactivity profiles

Current challenges in FAT2 antibody development include the limited availability of specific anti-Fat2 antibodies, necessitating the use of fosmid-based Fat2-GFP transgenes for localization studies in model organisms .